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Abstract  27 
Aim: Peri-implantitis is a common cause of late implant failure. Studies have investigated different 28 
treatment strategies. The effectiveness of these modalities, however, remains unclear. This study 29 
aimed to evaluate the success of surgical peri-implantitis treatment using clinical and radiographic 30 
parameters. 31 
Material and methods: A systematic review of published literature was employed. Key words were 32 
selected to conduct an electronic search using four databases for literature on human clinical 33 
studies. Meta-analyses were carried out for clinical probing, pocket depth and radiographic bone 34 
level.    35 
Results: A total of 16 papers met the inclusion criteria. Four treatment modalities to supplement 36 
mechanical debridement were identified: 1) apically-repositioned flap, 2) chemical surface 37 
decontamination, 3) implantoplasty and, 4) bone augmentation. Inconsistent results were evident 38 
which were dependent on several treatment-independent factors. No clinical benefits were 39 
identified for the additional use of surface decontamination, while limited evidence demonstrated 40 
improvement of clinical and radiographic outcomes after implantoplasty. The effect of bone 41 
augmentation appeared limited to ‘filling’ radiographic defects. 42 
Conclusions:  The outcomes of the currently available surgical interventions for peri-implantitis 43 
remain unpredictable. There is no reliable evidence to suggest which methods are the most 44 
effective. Further randomised-controlled studies are needed to identify the best treatment methods.    45 
 46 
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 48 
 49 
 50 
 51 
 52 
Clinical Relevance 53 
Scientific rationale for study: In the management of patients with peri-implantitis, the treatment 54 
of established bony defects around fixtures remains a significant clinical challenge.  Principal 55 
findings: Whilst a range of surgical treatment modalities have been described, from simple 56 
debridement to implantoplasty and attempted guided-tissue regeneration, the individual techniques 57 
employed often appear based on operator-preference. Practical implications: This systematic review 58 
sought to evaluate the existing evidence to compare the existing surgical treatment modalities, 59 
determine their effectiveness and inform the management of these patients, however, the 60 
outcomes remain unpredictable. Further studies are required to discover the optimal surgical 61 
treatment approach for peri-implantitis.  62 
 63 
Introduction  64 
Implants provide a long-term, generally predictable treatment to restore function 1, aesthetics 2, 65 
self-esteem 3, and quality of life 4 following tooth-loss. The application and use of dental implants 66 
has increased and now represents an indispensable therapeutic option for the replacement of 67 
missing teeth.  68 
Peri-implantitis is considered to be the main biological cause of 5-year implant failure 5, 6. 69 
Review studies have estimated that peri-implantitis will affect 28%-56% of patients and 12%–43% of 70 
individual implant sites 7, 8. This variation in prevalence may reflect differences in study design, 71 
population size and risk profiles, and the clinical ‘definition’ of peri-implantitis 7, 9. There remains a 72 
lack of evidence regarding treatment and prognosis of peri-implantitis 8. 73 
The inflammatory destruction of peri-implant tissue is multi-factorial. However, biofilm and 74 
bacterial infection are considered to be the major aetiological features in the development of peri-75 
implant disease 8. Smoking is also a strong predictor of implant failure 10, leading to an increase in 76 
prevalence that is 4.7 times greater than is observed in non-smokers 11 . Implant failure is 6 times 77 
greater in patients with a history of periodontitis than those who did not have a history of 78 
periodontitis 11. Systemic risk factors such as diabetes, cardiovascular diseases, age, gender, and 79 
genetics have been suggested as potential risk factors, although studies are limited 12, 13. Local risk 80 
factors, e.g. excess cement, was associated with signs of peri-implantitis in 100% of patient with a 81 
history of periodontal disease and 65% of healthy controls 14. 82 
The diagnosis of peri-implantitis depends on the presence of inflammatory signs, bleeding 83 
on probing (BOP) or suppuration on probing (SOP) and the degree of bone loss evident 84 
radiographically 15. However, it is important to distinguish this diagnosis of peri-implantitis from 85 
bone resorption resulting from bone remodelling which occurs early after implant placement 7. 86 
Some authors do not consider peri-implantitis as a differential diagnosis unless the implants have 87 
been in place for >12 months 16-18. 88 
The consensus report of the 11th European Workshop on Periodontology highlights steps to 89 
reduce the risk of incidence of peri-implantitis 19. The indications for appropriate management 90 
strategies that appear in clinical studies have resulted in development of the ‘cumulative 91 
interceptive supportive therapy’ 15, 20, 21. The management of peri-implantitis is based on similar 92 
techniques to those of periodontitis 11 which entail the elimination of inflammation and prevention 93 
of further bone loss; including non-surgical (conventional) and surgical treatment 22. Conventional 94 
non-surgical treatment can be classified into mechanical, chemical and light-mediated therapies. 95 
Reviews and meta-analyses have concluded that there is no reliable non-surgical treatment which 96 
results in elimination of the disease 23-25. 97 
Surgical treatment allows better access to the implant surface and the surrounding bony 98 
defect 26 and is used in conjunction with patient-directed care, and non-surgical therapy to reduce 99 
bacterial colonization and local inflammation 21. Mechanical debridement of the implant surface can 100 
be achieved using curettes, ultrasonic scalers, or air-abrasion, in the presence or absence of systemic 101 
antibiotics. A 3-month follow-up study has shown that mechanical debridement alone, following 102 
surgical access, is effective in reducing clinical/microbial parameters 27. Whilst adjunctive surface 103 
decontamination with antimicrobials such as chlorhexidine (CHX) reduced microbial counts, this had 104 
no significant effect on clinical or radiographic parameters 28, 29.  Leonhardt et al. (2003) reported 105 
that significant reduction in BOP and PPD (periodontal probing depth) following surgical 106 
debridement and decontamination with H2O230. Although many clinicians employ topical antibiotics 107 
e.g. tetracycline and minocycline, their clinical effect remains unclear 31.   108 
Lasers have been shown to have no additional clinical benefit as a potential surface-109 
decontamination agents during surgical therapy when compared with mechanical debridement 32, 33. 110 
Photo-dynamic therapy (PDT) was shown to significantly decrease BOP and PPD between test and 111 
control subjects in a randomised control trials (RCT), although the bacterial counts showed no 112 
difference between the two groups 34.  113 
Adjunctive resective surgery using osteoplasty, with or without apically re-positioned flap 114 
(ARF) procedures, has been reported to improve clinical sign of peri-implantitis, where PPD ≥ 6 mm 115 
were eliminated in 77% of subjects 35. However, the use of ARF in the aesthetic zone is limited 11. 116 
Implantoplasty is directed to reduce surface-roughness of the implant surface to decrease bacterial 117 
and biofilm accumulation 36. However, concerns have been raised regarding the reduction of implant 118 
strength 37, deposits of titanium particles in the soft- and hard-tissues 38 and increased marginal 119 
tissue recession and exposure of the implant surface 31. Re-osseointegration using bone 120 
augmentation (autogenous bone 39,40 and/or synthetic bone graft materials 41,42 may provide a 121 
significant improvement in clinical and radiographic parameters compared to the baseline. Bone 122 
graft (autogenous or synthetic), however, cannot be integrated on to a metal surface 43. 123 
Furthermore, it has been shown that the use of membrane/s with autogenous or synthetic materials 124 
has no additional benefit 40, 44. 125 
The aim of this systematic review was to critically evaluate the current literature on the 126 
surgical treatment of peri-implantitis and assess the effectiveness of treatment modalities (and 127 
adjunctive therapies) on peri-implant and periodontal radiographic outcomes. The objective was to 128 
identify the most predictable and reliable treatment modalities by a quantitative comparison of 129 
outcomes using meta-analysis. 130 
Materials and methods 131 
Search Strategy 132 
In order to achieve the aims of this study, an electronic literature search was conducted using Ovid 133 
MEDLINE, EMBASE and EBM Review – Cochrane Central Register of Control Trials and Cochrane 134 
Database of Systematic Reviews. The following keywords were combined: ‘Tooth Implantation’ OR 135 
‘Dental Implants’ OR ‘Tooth implants’ OR ‘Oral Implants’ OR ‘Endosseous implants’ OR 136 
‘Osseointegrated implants’ AND ‘Periimplantitis’ OR ‘Peri-implantitis’ OR ‘Peri-implant disease’ OR 137 
‘Peri-implant defect’ OR ‘Peri-implant infection’ OR ‘Peri-implant inflammation’ OR ‘Peri-implant 138 
bone loss’ AND ‘Management’ OR ‘Treatment’ OR ‘Therapy’ AND ‘Surgery’ OR ‘Surgical’ OR ‘Surgical 139 
approach’ OR ‘Open flap’ OR ‘Access flap’ OR ‘Resective’ OR ‘Regenerative’ OR ‘Bone regeneration’ 140 
OR ‘Bone augmentation’ (Table 1). 141 
 142 
Study Selection Criteria 143 
The criteria for inclusion of specific studies in this review were human studies published in the 144 
English language. Studies were selected for randomized controlled trials or prospective cohort 145 
studies only with ≥ 10 patients and ≥6 months follow-up (the longest follow up period was chosen in 146 
longitudinal studies which were published more than once). Experimental animal or studies in vitro 147 
were excluded. 148 
 149 
Primary and secondary outcomes 150 
The primary outcome for this review study was the reduction of BOP in implants treated surgically 151 
for peri-implantitis. The secondary outcomes were the assessment of PPD and RBL (radiographic 152 
bone loss). 153 
 154 
Qualitative assessment methods (Risk of bias) 155 
The modified ‘Critical Appraisal Skills Program’ (CASP) checklists was used to assess the quality of the 156 
studies 45. The risks of bias were categorized into; low risk (all the criteria were met), moderate risk 157 
(1-2 criteria were missed) or high risk (>2 criteria were missed). 158 
 159 
Statistical Analysis 160 
Meta-analyses were conducted separately for the parameters PPD and RBL using computer software 161 
(Stata® V13). All data used in meta-analysis were those measurements made at the end of the 162 
observation period for both control and intervention arms. Forest plots were produced to represent 163 
the standardized mean difference (SMD) between control and test groups. Pooled estimates and 164 
associated 95% confidence interval (CI) from meta-analysis for each type of intervention were 165 
indicated by ‘diamond’ symbols in Fig. 5; the center of the diamond (with respect to the x-axis) 166 
indicates the pooled point estimate and the edges indicate the pooled 95% CI. I-squared values and a 167 
chi-squared test were used to assess the heterogeneity of the studies.46 Where heterogeneity was not 168 
problematic fixed-effects meta-analysis was employed and random-effects meta-analysis was 169 
otherwise employed. Although some evidence of an outlier was observed for RBL for some studies 170 
49,50, results for this study were included in Forest plots because it was not used to form any ‘pooled’ 171 
estimates (it was the only study in the ‘implantoplasty’ group). 172 
 173 
Results 174 
Literature on peri-implant disease  175 
Initial results highlighted the increase in published research on peri-implant disease over the last 15 176 
years (Fig. 1a). There were significantly more publications on peri-implantitis and its surgical 177 
treatment compared to the numbers of publications regarding peri-implant mucositis and non-178 
surgical treatment (Fig. 1b). 179 
 180 
Manuscript selection 181 
The literature search identified 320 studies, and 25 were selected for full-text evaluation following 182 
title and abstract screening. A further 9 papers were excluded following careful review (Fig. 2), and 183 
the remaining 16 studies included and reviewed for detailed qualitative and quantitative assessment 184 
(see Supplementary Information for a summary of the included studies). Selection was based on the 185 
‘Preferred Reporting Items for Systematic review and Meta-Analysis’ flow chart PRISMA 48. Of the 16 186 
studies included, 9 were RCTs, 4 were comparative prospective studies, and 3 were single group 187 
prospective studies. The CASP checklist revealed that 53% of the included studies have a high risk of 188 
bias, 35% have a moderate risk, and the remaining studies (12%) have a low risk of bias. The follow-189 
up periods of the studies that were included in the review ranged from 6 to 60 months. However, 190 
the participants were observed for 12 months in most of the studies.   191 
 192 
 193 
 194 
Surgical interventions 195 
The main type of surgical intervention was bone augmentation following mechanical debridement, 196 
which was examined in 44% of the studies (Fig. 3a). The effect of mechanical debridement combined 197 
with surface decontamination was examined in 38% of the studies. Relatively few studies (12%) 198 
considered the effects of mechanical debridement only; 6% of the studies examined mechanical 199 
debridement with implantoplasty. Xenograft materials were used for 64% of the bone augmentation 200 
cases, whilst autogenous bone was used for 20% of the augmentation studies. CHX was the most 201 
common surface decontamination method (57%) and was used in all of the cases (which included 202 
debridement plus surface decontamination; Fig. 3b).  203 
 204 
Study outcomes 205 
The parameters used in clinical measurement of peri-implantitis were BOP, PPD, and RBL. The 206 
majority of studies used both clinical and radiographic outcomes (69%), and the remaining studies 207 
employed clinical parameters only (31%). Three studies 28, 29, 49 measured change in outcome 208 
measurements with time (3, 6, and 12 months follow-up) and they showed that the mean BOP was 209 
significantly decreased (P < 0.05) after 3 and 6 months followed by a gradual increase from 6 to 12 210 
months (Fig. 4a). The mean PPD was also decreased significantly (P < 0.05) at 3-month follow-up 211 
then remained relatively constant during the remaining periods (Fig. 4b). By contrast, RBL had not 212 
increased significantly (P > 0.05) after 3 months. 213 
 214 
Meta-analysis  215 
The meta-analysis was conducted using 8 RCTs 28, 29, 32, 34, 50-53 and 2 controlled prospective cohort 216 
studies 40, 44 as they reported mean reductions (and standard deviations) for PPD and RBL. The forest 217 
plots for PPD and RBL are represented by the four methods for surgical peri-implantitis treatment 218 
identified: 1) surface decontamination, 2) implantoplasty, 3) bone augmentation, and 4) additional 219 
use of membranes in bone regeneration. Few studies have published data relating to BOP, and so no 220 
meta-analysis could be conducted for this parameter.  221 
Meta-analysis demonstrated that implants treated with surface decontamination had SMD of -0.21 222 
(95% CI: -1.70 to 1.27) for PPD reduction. Only one study 50, 51 reported the effect of implantoplasty 223 
on PPD reduction which shows a significant SMD of -3.33 (95% CI: -4.37 mm to -2.28 mm). Bone 224 
augmentation with grafting materials and the additional use of membrane resulted in SMD of 0.15 225 
mm (95% CI: -0.55 to 0.84 mm) and 0.30 mm (95% CI: -0.31 to 0.91 mm) respectively (Fig. 5a). In 226 
terms of RBL changes, the use of surface decontamination methods resulted in SMD of 0.54 mm 227 
(95% CI: -0.20 to 1.28 mm). Whereas implant treated with implantoplasty, had SMD of -3.38 (95% CI: 228 
-4.43 to -2.33 mm). The SMD for RBL changes after the use of bone augmentation was -1.50 (95% CI: 229 
-0.80 to -0.31 mm). However, the additional use of membrane has SMD of -0.16 (95% CI: -0.56 to 230 
0.24 mm) (Fig. 5b). Whilst implantoplasty and bone augmentation resulted in significant 231 
improvement in RBL, the use of surface decontamination or additional membrane application failed 232 
to significantly affect observed treatment outcomes.  233 
Heterogeneity was found to be small or moderate for the additional membrane subgroup 234 
(i.e.: RBL, I-squared = 0.0%, P = 0.64; PPD, I-squared = 52.1%, P = 0.152) and so random-effects meta-235 
analysis should provide a reasonable pooled estimates in this case. Heterogeneity was found to be 236 
high for the surface decontamination subgroup (i.e.: RBL, I-squared = 88.6%, P < 0.001; PPD, I-237 
squared = 97.1%, P < 0.001). A sensitivity analysis for RBL and for the additional membrane subgroup 238 
could not be carried out for due to the small number of studies in this case. A sensitivity analysis 239 
could be carried out for PPD for this subgroup, where removal of the study with the smallest sample 240 
size of seventeen subjects in total (namely, Schwartz et al., 2013) did not affect pooled results very 241 
greatly (i.e., SMD = -0.253 and 95% CI = -2.001 to 1.494), whereas removal of the only “outlying” 242 
study that indicated a positive mean difference (namely, de Waal et al., 2015) did affect pooled 243 
results (i.e., SMD = -0.866 and 95% CI = -1.663 to -0.069). This result indicates a significant reduction 244 
in PPD for surface decontamination subgroup in this circumstance, although caution should still be 245 
exercised due to the small number of studies and heterogeneity. Again, funnel plots are likely to 246 
yield limited information only due to the small number of the studies included in the analysis. 247 
 248 
Discussion 249 
This systematic review and meta-analysis was conducted to explore the literature relating to the 250 
surgical management of peri-implantitis. It was evident that the patient selection criteria for entry 251 
into the studies (and the definition of ‘peri-implantitis’) varied considerably between the included 252 
studies. For example, one study defined peri-implantitis by implants with RBL indicating >50% of 253 
bone loss 40, whereas other studies defined peri-implantitis as affecting implants that exhibited PPD 254 
>6mm with radiographically visible bony defects 32, 54, 55.  255 
Radiographic interpretation of results was found to be inconsistent. Defect configuration 256 
needs to be taken into account, and this is particularly evident where bone regeneration is to be 257 
attempted using guided bone regeneration 55. Roccuzzo et al. (2016) went on to show that the 258 
circumferential defects showed better bone regeneration compared with the other types of defect. 259 
However, another four-year study which included combined surgical therapy, surface 260 
decontamination, and implantoplasty revealed that the outcomes were not directly affected by the 261 
defect configuration 32. 262 
Plaque control is pivotally important in peri-implant disease and response to treatment 15. 263 
Adequate oral hygiene maintaining plaque scores at lower levels (PI ≤ 1) was important for reducing 264 
the incidence of BOP 56.  The severity of peri-implantitis at the commencement of treatment (as 265 
measured by the PPD and RBL) may clearly influence treatment outcomes 35, 57. Other important 266 
plaque-retentive factors, e.g. surface roughness are an important consideration when conducting 267 
comparative studies 49, 53, 54. A history of both smoking and periodontitis has been shown to have an 268 
adverse effect on the treatment of peri-implantitis 44, 52, 58. Due to the small numbers of patients, 269 
variation in tobacco usage, and incomplete assessment of the severity of the previous periodontal 270 
disease in the papers included within this study, this correlation could not be linked to the outcomes 271 
of surgical peri-implantitis treatment. 272 
The definition of a successful treatment also varied between studies. In marked contrast, 273 
some studies 49 simply considered the survival of the affected implants following treatment to 274 
represent success. Other studies 28, 29, 53, 57 have considered no further bone loss and presence of PPD 275 
≤ 5mm, with no BOP, to be a successful treatment.  Inter- and intra-examiner bias may also lead to 276 
variable in outcome measures, for example, force of probing 59. Furthermore, PPD alone is 277 
considered as an invalid marker for the progression of the disease as the reduction in PPD post-278 
treatment may simply reflect gingival recession and/or the surgical technique e.g. apically-279 
repositioned flap procedures 52, 60. Although radiographic assessment is the only truly non-invasive 280 
method for measuring marginal bone levels 52 it can only indicate ‘defect-fill’ but not the actual re-281 
osseointegration 44 and represents the mesial and distal bone levels only  61. More recently, cone-282 
beam CT has been used to detect the levels of buccal and lingual bones, although concerns have 283 
been raised regarding both radiation exposure and their validity due to a radiolucent halo that may 284 
occur around the implant 51.  285 
The rationale behind the use of adjunctive systemic antibiotics in the management of peri-286 
implantitis was considered in three studies 40, 49, 58. There is a lack of evidence to support the 287 
prescription of antibiotics in peri-implantitis treatment, which appears operator-dependent. An RCT 288 
investigating the effectiveness on systemic antibiotics failed to demonstrate any effect on local 289 
microbiological parameters within the defect 53. 290 
The most popular surface decontaminant was CHX, which has been tested extensively and 291 
approved to have a broad-spectrum anti-bacterial activity 62. Variation occurred in the CHX 292 
concentrations used in two studies (0.12% CHX Vs placebo29 or 2% CHX Vs 0.12% 28). Although both 293 
studies reported reduced microbial loads when compared to control groups, this did not translate 294 
into demonstrable clinical effects on peri-implantitis. Although other chemical antimicrobial 295 
treatments were employed e.g. H2O2, H3PO4, and EDTA, no studies compared their effects to other 296 
adjunctive treatments (or placebo-treated control groups).  A 4-year review revealed that curette 297 
and saline mechanical debridement showed better results than those treated with Er:YAG laser 32, 298 
although one study indicates that the Er:YAG laser gave better outcomes at 2-year follow-up 63.  299 
Meta-analysis failed to detect any significant difference in the use of surface decontamination (via 300 
CHX or Laser) on PPD and RBL. Previous studies have indicated that treatment results are 301 
independent of decontamination method and that other risk factors such as oral hygiene, defect 302 
configuration are better predictors of treatment success 33, 55. 303 
Implantoplasty reduces the macro-surface texture (threads) of the implants. The authors 304 
feel that the procedure is effective, partly as it is associated with complete elimination of the 305 
primary aetiological factor in peri-implantitis- namely the biofilm. Barbour et al. (2007) reports that 306 
it may increase the micro-surface roughness leading to biofilm retention. Furthermore, it may alter 307 
implant strength 37, 64 and increase the temperature of the implants surface 65, leading to adverse 308 
effects on bone cellularity 66. The significant improvement of clinical and radiographic parameters 309 
following implantoplasty was only based on one study 50, 51 and further research regarding this 310 
method is needed.  311 
Bone augmentation is limited due to the biological principle of bone regeneration which 312 
needs a blood supply to provide nutrition, inflammatory cells to induce bone formation 313 
(osseoinduction), and collagen matrix for osseoconduction 43. The significant effect of bone 314 
augmentation on RBL relates to the bone grafts material occluding the defect; no effect on clinical 315 
outcome (PPD) is evident 52. Autogenous bone particles ± membranes in multi-walled defects 316 
resulted in significant improvement in PPD and RBL at 36 months 40. In contrast, Aghazadeh et al. 317 
(2012) demonstrated that bovine-derived xenograft (BDX) was more effective than autogenous 318 
particulate bone 58.  Khoury and Buchmann (2001) and Roos-Jansåker et al. (2014) were unable to 319 
demonstrate any additional benefits in comparison to defects treated with graft material alone 40,44.  320 
There are several limitations of this current study due to the inclusion of English language 321 
papers only, as well as considerable variability between the different studies included in this review 322 
relating to the inclusion/ exclusion criteria. Furthermore, there were only a small number of studies 323 
included for each type of surgical intervention, with most studies consisting of relatively small 324 
sample sizes and high risk of selection bias in patient inclusion. The high degree of heterogeneity 325 
between studies prevents quantitative comparison between the groups 47. Therefore, neither the 326 
differences between the groups nor the overall results were calculated. Furthermore, the meta-327 
analyses should be interpreted cautiously because of the small number of the included studies in 328 
each group and the high degree of heterogeneity between them.   329 
This current review concludes that a need exists for a long-term, double blind RCT with large 330 
sample size and split-mouth technique are required to eliminate patient-related bias. In addition, all 331 
potential confounders should be taken into account. Finally, it would be helpful if the definition, 332 
diagnosis and the outcomes of the disease were standardised, to be able to conduct more precise 333 
reviews, meta-analyses and the evidence-based surgical treatment of these patients. 334 
 335 
 336 
 337 
Conclusion  338 
This systematic review shows that a surgical approach to mechanical debridement alone may result 339 
in improved clinical outcomes, with no evidence to show the benefits of apically-repositioned flap 340 
procedures. No additional clinical benefits were found from the use of surface decontaminants 341 
(chemicals or lasers) or additional systemic antibiotics. A single study demonstrated a significant 342 
improvement following implantoplasty. Bone augmentation improved radiographic bone levels; the 343 
use of additional membrane/s, however, did not result in any additional benefit. The high degree of 344 
heterogeneity and the small number of controlled studies make it difficult to identify which 345 
procedure is superior to any other.  346 
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Figure legends: 516 
Figure 1 Publishing rate of papers on (a) peri-implant disease and (b) peri-implantitis treatment in 517 
the period 2001-2015. 518 
 519 
Figure 2 PRISMA flow chart for study selection. 520 
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Figure 3 Proportion of (a) surgical intervention investigated and (b) surface decontamination 522 
methods used in the included studies. 523 
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Figure 4 The relationship between observed outcomes and time for (a) BOP and (b) PPD 28, 29, 49. 525 
 526 
Figure 5 Forest plot for (a) probing pocket depth (PPD) reductions and (b) radiographic bone level 527 
(RBL) changes. 528 
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